Front Range Pharma gets FDA OK for Long COVID trial of FRP-003
Front Range Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FRP-003, allowing it to proceed with a Phase 2 clinical trial in adults with Long COVID and persistent fatigue. The company received notification from the FDA on September 30,